Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

Summary

This pilot study aims to evaluate whether a single dose of PCSK9 inhibitor administered after percutaneous coronary intervention (PCI) can improve long-term cardiovascular outcomes in patients with high post-PCI lipid core burden, as assessed by NIRS-IVUS. The study will assess major adverse cardiovascular events (MACE) over a 12-month follow-up period.

Timeline

Start

2025-07

Primary completion

2030-06

Completion

2030-07

Publications

• Kim W, Park S, Shin JH, Kook H, Lim YH. Proactive, short-term PCSK9 inhibition after PCI in patients with coronary artery disease at high residual risk: rationale and design of the randomized HANYANG-PICK trial. Front Cardiovasc Med. 2026 Mar 2;13:1761093. doi: 10.3389/fcvm.2026.1761093. eCollection 2026.

Drugs

Indications